Most linked-to categories

Showing below up to 50 results in range #51 to #100.

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)

51. Ovarian cancer medications‏‎ (29 members)
52. Renal cell carcinoma medications‏‎ (28 members)
53. Supportive medications‏‎ (28 members)
54. Urothelial carcinoma medications‏‎ (27 members)
55. Cholangiocarcinoma medications‏‎ (27 members)
56. CNS lymphoma medications‏‎ (27 members)
57. FDA approved in 2020‏‎ (26 members)
58. Transformed lymphoma medications‏‎ (26 members)
59. Cervical cancer medications‏‎ (26 members)
60. Endometrial cancer medications‏‎ (25 members)
61. FDA approved in 2015‏‎ (25 members)
62. Hematology & Oncology fellowship programs‏‎ (25 members)
63. Antimetabolites‏‎ (25 members)
64. Non-small cell lung cancer, nonsquamous medications‏‎ (24 members)
65. Classical hematology medications‏‎ (24 members)
66. FDA approved in 2017‏‎ (24 members)
67. PDGFR inhibitors‏‎ (24 members)
68. Myelodysplastic syndrome medications‏‎ (24 members)
69. Neuroblastoma medications‏‎ (23 members)
70. Head and neck cancer medications‏‎ (23 members)
71. Marginal zone lymphoma medications‏‎ (23 members)
72. Microtubule inhibitors‏‎ (23 members)
73. FDA approved in 2023‏‎ (22 members)
74. FDA approved in 2022‏‎ (22 members)
75. Vesicant‏‎ (22 members)
76. FDA approved in 2019‏‎ (22 members)
77. VEGFR inhibitors‏‎ (22 members)
78. REMS program‏‎ (22 members)
79. HIV-associated lymphoma medications‏‎ (22 members)
80. Non-small cell lung cancer, squamous medications‏‎ (21 members)
81. Breast cancer medications (historic)‏‎ (21 members)
82. Soft tissue sarcomas‏‎ (21 members)
83. T-cell acute lymphoblastic leukemia medications‏‎ (21 members)
84. KIT inhibitors‏‎ (21 members)
85. Bladder cancer medications‏‎ (21 members)
86. Chronic myeloid leukemia medications‏‎ (20 members)
87. Malignant solid neoplasm‏‎ (20 members)
88. Gastrointestinal cancers‏‎ (20 members)
89. Glioblastoma medications‏‎ (20 members)
90. Anticoagulants‏‎ (20 members)
91. Testicular cancer medications‏‎ (20 members)
92. B-cell lymphomas‏‎ (19 members)
93. MALT lymphoma medications‏‎ (19 members)
94. FDA approved in 2021‏‎ (19 members)
95. Classical hematology regimens‏‎ (19 members)
96. Pancreatic NET medications‏‎ (19 members)
97. Regimen index‏‎ (19 members)
98. Primary mediastinal B-cell lymphoma medications‏‎ (19 members)
99. Neuroendocrine tumor medications‏‎ (19 members)
100. Pancreatic cancer medications‏‎ (19 members)

View (previous 50 | next 50) (20 | 50 | 100 | 250 | 500)